The New Pragmatism: Clinical Trials, Investment and Regulations Post-COVID-19

July 30, 2020

Once the COVID-19 pandemic passes or is contained, the world will look and work very differently. The biopharmaceutical industry is no exception. In this podcast, Peyton Howell, Parexel’s Chief Commercial and Strategy Officer, talks with Paul Bridges, Worldwide Head of Regulatory and Access, and Sheela Hegde, a Partner with Parexel’s Health Advances subsidiary, about the regulatory, investing and clinical development changes that are most likely here to stay – The New Pragmatism.

Previous Flipbook
How to interact virtually with health authorities
How to interact virtually with health authorities

Next Article
I Can See More Clearly Now – FDA Issues Needed Guidance on Inspection Policies During COVID-19
I Can See More Clearly Now – FDA Issues Needed Guidance on Inspection Policies During COVID-19

On August 19, FDA published the final guidance Manufacturing, Supply Chain, and Drug and Biological Product...